Featured Research

from universities, journals, and other organizations

Low Education Predicts Lower Quality Of Life For Prostate Cancer Patients

Date:
April 13, 2007
Source:
University of California - San Francisco
Summary:
Among men who have received similar treatments for prostate cancer, those with less education ---- particularly those who did not graduate from high school ---- experience a significant drop in their quality of life after treatment compared with men who have more education.

Among men who have received similar treatments for prostate cancer, those with less education ---- particularly those who did not graduate from high school ---- experience a significant drop in their quality of life after treatment compared with men who have more education, according to a study led by researchers at the San Francisco VA Medical Center (SFVAMC).

"These men did not start out with a lower quality of life before cancer," says lead author Sara J. Knight, PhD, a staff psychologist at SFVAMC. "What's surprising is that after treatment, they have clinically significant problems across the board ---- mental and emotional as well as physical ---- in managing their lives."

The authors acknowledge that low educational level is often associated with lower income, which can lead to lower quality of life, but stress that for the men in their study, low education alone was associated with lower quality of life, irrespective of income. "In our analysis, it's their lower educational level that has made them more vulnerable to the effects of prostate cancer and its treatment," says Knight, who is also an assistant professor of psychiatry and urology at the University of California, San Francisco (UCSF).

The researchers analyzed the results of a self-reported quality-of-life survey completed by 248 patients who were diagnosed with prostate cancer between 1989 and 2002 and treated at three Veterans Affairs medical centers. Treatments included surgery, radiation therapy, hormone therapy, and observation or "watchful waiting."

After adjusting for a host of factors including severity and stage of cancer, treatment, age, education, income, marital status, and other diseases, the researchers found that men without high school diplomas "experienced greater decline and less recovery" during the first year after prostate cancer treatment across a wide variety of domains, including physical, emotional, and social functioning, vitality, mental health, general health, urinary function, and sexual function.

"More generally, the lower your educational level, the greater the likelihood that you would have a lower quality of life after diagnosis and treatment," says Knight. She points out a key aspect of the study: The subjects, as VA patients, all had equal access to the same quality of health care. "Since health care access is a key factor in predicting health outcomes, it's significant that we were able to control for this variable," she says.

The good news, she says, is that clinicians across the country can immediately begin to identify and help prostate cancer patients who are at greater risk for poor quality of life. "We can identify these men by their educational levels, ask them what difficulties they're having in managing their day-to-day lives, and try to provide them with the appropriate resources." She notes that VA medical centers offer a broad range of counseling and referral services to help veterans with mental, emotional, career, and other problems.

Knight says that the study is "as far as we know, the first to emphasize the impact of educational level on quality of life after prostate cancer treatment, as opposed to health literacy, a much more narrow measure which we've known for some time has an effect on health outcomes."

The study authors indicate they do not know why education plays such a large role in determining quality of life after prostate cancer treatment. One reason, they say, might be that "even in an equal-access health care system" such as the VA, men with less education have more trouble understanding educational materials about prostate cancer, its treatment, and post-treatment management, which in turn may lead to poorer disease management, greater worry, and greater difficulty adjusting to life as a cancer survivor.

"If that's the case, then we can begin to address the problem by creating educational materials that are better targeted to men with less education," says Knight.

She says another possible explanation is economic: "Men with less education might, indeed, have fewer financial resources, so prostate cancer is going to have a greater negative impact on their lives. For example, if you're driving a cab or working on a delivery truck, urinary dysfunction can become extremely disabling. It's hard to manage your symptoms, take breaks, and get enough rest when you're worried about keeping your job."

Knight stresses that, thanks to today's effective treatments, "men with prostate cancer can live a long time. If these problems go unaddressed, these men will have a much worse time over the course of their lives."

The researchers caution that because their study is based on results from only three VA medical centers, additional research will be needed to determine if the results can be generalized to all VA patients or to men in general.

Co-authors of the study are David M. Latini, PhD, of Baylor University and the Houston VA Medical Center; Stacey L. Hart, PhD, of SFVAMC and UCSF; Natalia Sadetsky, MD, MPH, of UCSF; Christopher J. Kane, MD, of SFVAMC and UCSF; Janeen DuChane, PhD, of Baxter International, Inc.; and Peter R. Carrol, MD, of UCSF. Patients in the study were enrolled in Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a nationwide longitudinal observational study of prostate cancer patients. Carroll is principal investigator of CaPSURE and Sadetsky is a CaPSURE investigator.

The paper is available in the on-line Early View section of the journal Cancer. The study was funded by the National Institutes of Health and UCSF. CaPSURE is supported by TAP Pharmaceutical Products Inc.


Story Source:

The above story is based on materials provided by University of California - San Francisco. Note: Materials may be edited for content and length.


Cite This Page:

University of California - San Francisco. "Low Education Predicts Lower Quality Of Life For Prostate Cancer Patients." ScienceDaily. ScienceDaily, 13 April 2007. <www.sciencedaily.com/releases/2007/04/070412174213.htm>.
University of California - San Francisco. (2007, April 13). Low Education Predicts Lower Quality Of Life For Prostate Cancer Patients. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2007/04/070412174213.htm
University of California - San Francisco. "Low Education Predicts Lower Quality Of Life For Prostate Cancer Patients." ScienceDaily. www.sciencedaily.com/releases/2007/04/070412174213.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins